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Even though cancer has been one of the most funded research topics in the last decades, it is 
still one of the leading causes of death, second only to cardiovascular diseases (Howlader et 
al. 2012). Despite tremendous efforts to predict, treat, and cure cancer, a lot of questions re-
main unanswered and prognosis for certain types of cancer is still very poor.  
Colorectal cancer represents one of the most important cancer entities, accounting for about 
70.000 newly diagnosed cancer cases per year in Germany alone, leading the statistic before 
breast cancer (about 46.000) and lung cancer (about 37.000) as detailed in the “Gesundheits-
bericht für Deutschland” published by the Robert Koch-Institut in Berlin, Germany. Colorec-
tal cancer is also one of the leading causes of cancer-related death accounting for over 25.000 
deaths in Germany each year. Most cases are of sporadic origin with only 5-10% representing 
hereditary cancers (Lynch and de la Chapelle 2003). The median age of diagnosis lies be-
tween 60 and 70 years, with a steep increase in incidence after 50 years of age. As a conse-
quence, regular colonoscopies are recommended from age 55 (for patients without additional 
risk factors) onward to detect developing carcinomas early and start treatment when the prog-
nosis is still good. In general, risk factors for the development of colorectal cancer are age, 
gender (higher risk for males), alcohol, high caloric diet, raw meat, and a sedentary lifestyle. 
Treatment decisions are based upon the tumor staging following the TNM classification (“T” 
depicts depth of invasion, “N” lymph node status, and “M” presence of distant metastasis) put 
forth by the UICC (Union for International Cancer Control, Sobin and Fleming 1997). This 
study focuses on locally advanced rectal cancer (UICC stage II/III). 
The standard treatment for locally advanced rectal cancers consists of preoperative 5-
fluorouracil (5-FU)-based chemoradiotherapy followed by radical surgery. Preoperative 
chemoradiotherapy is employed to reduce tumor burden, improve resectability, and to in-
crease the chance to completely resect the tumor. Furthermore, this multimodal approach re-
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duces local recurrence (Sauer et al. 2004). However, the clinical response to chemoradiother-
apy varies greatly, and a considerable percentage of rectal cancers are “chemoradioresistant”, 
meaning they are largely unaffected, even when intensified regimens of chemoradiotheray are 
being pursued (Cunningham et al. 2010). This represents a substantial clinical and socioeco-
nomic problem. It is thus of utmost clinical importance to determine the molecular character-
istics underlying this resistance and to identify effective strategies to overcome it (Kuremsky 
et al. 2009). Previously, we have therefore used gene expression profiling of resistant and 
responsive rectal cancers from patients who had been treated with preoperative chemoradio-
therapy within a phase III clinical trial and identified a set of genes correlated with resistance. 
One of the genes that was identified as significantly overexpressed in resistant tumors was T 
cell factor 4 (TCF4, also, and more correctly named TCF7L2) (Ghadimi et al. 2005). TCF7L2 
represents a key transcription factor that mediates canonical Wnt signaling, plays a central 
role in embryonic development and in the maintenance of tissue homeostasis (Clevers 2006, 
Klaus and Birchmeier 2008, Moon et al. 2004). In cells with an inactive canonical Wnt path-
way, ȕ-catenin, the main cofactor of TCF7L2 and required for transcription activity, is de-
graded by the so-called “destruction complex”. This complex mainly consists of the scaffold 
protein Axin, which binds two other key components, Adenomatous Polyposis Coli (APC) 
and Glycogen Synthase Kinase-3 (GSK-3) (Clevers 2006). Binding of Wnt ligands to cell 
surface receptors of the Frizzled family inhibits glycogen-synthase-kinase-3ȕ-mediated phos-
phorylation of ȕ-catenin, and subsequently halts its degradation, leading to the stabilization of 
ȕ-catenin and its accumulation in the nucleus. This results in binding of ȕ-catenin to members 
of the TCF and lymphoid enhancer-binding factor family of transcription factors, which then 
induces or represses transcription of a plethora of target genes (Nusse 1999). For example, 
cMyc, one of the most famous oncogenes, is regulated by TCF7L2 signaling as well as sever-
al cell cycle genes (e.g. CCND1) and genes involved in apoptosis and cellular survival path-
ways (e.g. survivin). A comprehensive list of target genes and in-depth information about the 
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Wnt pathway can be found on the “Wnt homepage” 
(http://www.stanford.edu/group/nusselab/cgi-bin/wnt/), one of the best resources for infor-
mation about the Wnt signaling pathway. 
Furthermore, in the multistep carcinogenesis of colorectal cancers, deregulation of the Wnt 
pathway represents one of the main steps. During cancer development the APC gene (Ade-
nomatous Polyposis Coli), which usually inhibits Wnt signaling as part of the destruction 
complex, is commonly mutated and the pathway is constitutively active, leading to an uncon-
trolled activation of transcription (Markowitz and Bertagnolli 2009). Other studies have 
shown that aberrant Wnt signaling promotes colorectal cancer (CRC) development (Clevers 
2006, Klaus and Birchmeier 2008, Moon et al. 2004).  Despite these studies, the Wnt signal-
ing pathway has not yet been associated with treatment resistance of rectal cancer to chemo-
radiotheray. In this study, we therefore tested whether the observed overexpression of 
TCF7L2 is of functional relevance for mediating chemoradioresistance in rectal cancer. 
2. METHODS 
2.1 Cell lines / media / cell culture 
Eight human colorectal cancer cell lines were included in this study (Caco-2, HT-29, 
SW1116, SW1463, SW480, SW620, SW837 and WiDr). All cell lines were cultured in their 
ATCC-recommended media, supplemented with fetal bovine serum and glutamine. No anti-
biotics were used except for selection of stably transfected clones. During culture cells were 
kept at around 60% confluence (log-phase growth), subcultured at least twice a week, and 
media were regularly renewed. Furthermore, cells were regularly tested for mycoplasma in-
fection by polymerase chain reaction (PCR). Functional experiments were performed in 
SW480, SW837 and HT-29.  
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2.2 shRNA vectors, plasmids and primers 
RNAi-mediated silencing of TCF7L2 was performed using two different short-hairpin con-
structs (shRNA) for each of the three cell lines. A scrambled shRNA construct served as con-
trol (negative control, shNeg). Bacterial stocks were obtained from OpenBiosystems (pGIPZ 
lentiviral vector, ThermoFisher Scientific, Huntsville, AL), grown according to the manufac-
turer's manual, and vector DNA was extracted using the Endotoxin-free Maxi Prep extraction 
Kit from Qiagen (Hilden, Germany). Vector DNA was tested for proper extraction using re-
striction digestion with the Sal1 restriction endonuclease (New England Biolabs, Ipswich, 
MA, USA). Before transfection, vector DNA was linearized using Fsp1 (New England Bi-
olabs) (unique restriction site) and purified to ensure optimal transfection conditions. The 
shRNA vectors contain a puromycin selection cassette and a GFP cassette which was used for 
selection and determination of transfection efficiency, respectively. All other vectors 
(TOPFLASH, FOPFLASH, CMV-renilla, S33Y-ȕ-catenin) were used in a similar way, but 
were not linearized. Primers were designed as exon-spanning to ensure specificity for RNA 
molecules. 
2.3 Transfection and establishment of stable cell clone populations 
All cell lines were transfected using the Amaxa Nucleofection technique (Lonza, Cologne, 
Germany), comprising of a proprietary lipid solution combined with a proprietary electro-
poration method as detailed in the manufacturer's manual. In test experiments, the following 
transfection protocol and parameters were established to be most effective: At the time of 
transfection, log-phase cells were subcultured, and for each transfection 1 million cells were 
added to 2.5µg vector DNA as well as 100µl of the Amaxa Nucleofection solution. Cells were 
transfected using an optimized Amaxa Transfection program (T-30). After transfection, cells 
were transferred to a 1.5ml Eppendorf tube filled with RPMI medium for 15 minutes, and 
then to a 6-well plate filled with the recommended cell line medium. Twenty-four hours after 
transfection, the medium was renewed. In the case of stable transfections, selection was start-
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ed 48 hours after transfection using media with 0.8% or 1.2% puromycin (for SW480/SW837 
and HT-29, respectively). This selection process was employed to ensure that only cells ex-
pressing the transfected vector remained. For the stable cell lines, single cell cloning (SCC, 
single cell clone) was performed after selection to ensure experimentation with homogenous 
cell populations. The process works as follows: a cell solution is serially diluted to about one 
cell per 300µl of medium. This solution is then pipetted into a 96-well plate. Twenty-four 
hours later, each well of the 96-well plate is carefully screened by microscopy, and each well 
containing only a single cell is marked. This cell will then start to divide, grow into a colony, 
and eventually fill up a whole cell culture flask, forming a population based on single cell, 
hence “single cell cloning”. 
2.4 Cell lysis and western blot analysis 
After removal of the cell culture medium, around 100µl of a NP-40 based cell lysis buffer 
containing protease inhibitor (Proteo Block, Fermentas, St. Leon-Rot, Germany), DTT (Ap-
pliChem, Darmstadt, Germany) and PhosphoStop (Roche, Mannheim, Germany) was added 
to each well of a 6-well plate. Next, cells were scraped from the culture surface, and the sus-
pension was transferred to Eppendorf tubes. Cells were then lysed on ice for 30 minutes. The 
cell suspension was cleared from cell debris by centrifugation at 4°C, and the supernatant 
containing the protein was stored at -20°C. For separate extraction of nuclear and cytosolic 
protein fractions, cells were lysed using a NP-40-based lysis buffer, and fractions were sepa-
rated by serial centrifugation. Prior to using the proteins for western blotting, a 4X SDS-based 
loading buffer was added and the amount needed for blotting was incubated at 95°C for 5 
min. Blotting was performed using a semi-dry blotting apparatus (Biometra, Göttingen, Ger-
many). For blocking, 5% blocking milk was used. All antibodies were used according to their 
respective datasheets. Antibodies were used in at the respective conditions:  anti-TCF7L2 (5% 
BSA, 1:10,000, incubation at 4°C for 16h; Abcam, Cambridge, UK), anti-ȕ-actin (5% milk, 
1:1,000, incubation at 4°C for 16h; Sigma-Aldrich, Steinheim, Germany), anti-active-ȕ-
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catenin (5% milk, 1:2,000, incubation at 4°C for 16h; Millipore, Schwalbach, Germany) and 
anti-ȕ-catenin (5% milk, 1:2,000, incubation at 4°C for 16h; Santa Cruz Biotechnology, Hei-
delberg, Germany).  
2.5 Irradiation experiments 
For irradiation experiments, log-phase cells were seeded into 6-well plates at specific cell-
line-dependent cell densities, depending on cellular growth characteristics (between 250 and 
1,000 cells per well were seeded). Subsequently, sixteen hours after seeding, cells were irradi-
ated with a single dose of 1, 2, 4, 6 and 8 Gy of X-rays at 1 Gy/min (Gulmay Medical Ltd, 
Camberley, UK). Each experiment contained an unirradiated control set, which was exactly 
treated like the irradiated set.  Depending on cellular growth characteristics, clones were 
grown for 8 days (HT-29), 10 days (SW480) or 21 days (SW837). Optimal cell densities, 
growth time and other growth condition were determined in test experiments. During the 
growth period, the culture medium was refreshed every third day. At the end of the growth 
period, cells were taken out of the incubator, medium was removed, and the colonies were 
fixed with 70% ethanol and stained using either crystal-violet (SW480) or haemalaun (SW837 
and HT-29). Colonies with more than 50 cells were scored as survivors (Franken et al. 2006). 
Each experiment was performed in triplicate and independently repeated three times. 
2.6 Cell cycle 
Cell cycle distribution was analyzed before, and 4 and 8 hours after irradiation at 4 Gy. Cell 
cycle analyses were performed as follows: Cells were harvested by trypsinization at the indi-
cated time points. Cell membranes were permeabilized at -20°C overnight using 70% metha-
nol. Subsequently, cells were treated with 10 µl/ml RNase A (Qiagen) for 30 min at 37°C, and 
stained with 20 µl/ml propidium iodide (Sigma–Aldrich) for 20 min at 37°C. DNA content 
was measured by flow cytometry (FACScan; BD Bioscience, Germany), and at least 30,000 
cells were counted for each sample. All experiments were independently repeated three times. 
Results were analyzed using the FlowJo software package (Tree Star, Ashland, OR). 
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2.7 DNA damage repair 
DNA damage repair was studied by evaluating the cell’s ability to sufficiently repair DNA 
double strand breaks (DSBs). Towards this goal, the levels and kinetics of the phosphorylated 
form of the histone protein H2AX, which accumulates at sites of DSBs (Lobrich et al. 2010), 
were studied. Cells were grown on microscopy slides for 16 hours, irradiated at 2 Gy and fix-
ated with 2% formaldehyde/phosphate-buffered saline for 15 min. Following fixation, cells 
were permeabilized with 0.2% Triton X-100/phosphate-buffered saline/1% fetal bovine serum 
(Pan, Aidenbach, Germany) for 10 min on ice, and blocked with 5% bovine serum albu-
min/1% fetal bovine serum/phosphate-buffered saline. Slides were incubated over night at 
4°C with a mouse anti-JH2AX antibody (Millipore) and an appropriate secondary antibody 
(fluorescence-coupled mouse anti-rabbit antibody) (Millipore). Nuclei were counterstained 
with 4’,6-diamidino-2-phenylindole (Sigma–Aldrich) and mounted using VECTASHIELD 
(Vector Laboratories, Peterborough, UK). Radiation-induced JH2AX foci were counted in at 
least 100 cells per sample using a fluorescence microscope (DM6000; Leica, Wetzlar, Ger-
many). Pictures were taken using the Leica Application Suite. 
2.8 TCF transcriptional activity 
A TCF reporter assay (TOPFLASH/FOPFLASH assay, Korinek et al. 1997) containing two 
luciferase reporter plasmids was used to measure the TCF transcriptional activity. The first 
plasmid (TOPFLASH, Millipore) contains six TCF binding sites, attached to a firefly lucifer-
ase which is activated upon binding of TCFs. The second plasmid (FOPFLASH) contains six 
mutated TCF binding sites and serves as a negative control. A second vector (CMV-renilla), 
constitutively expressing a renilla luciferase, is used for normalization for differences in trans-
fection efficiency and cellular viability. This system measures the transcriptional baseline 
activity of the TCFs. Furthermore, the inducibility of transcriptional activity was tested by co-
transfection of mutated (S33Y, activating mutation) ȕ-catenin. ȕ-catenin in its active state 
binds to TCF7L2 and increases the transcriptional activity of the complex, thus enhancing 
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reporter activity (Schwarz et al. 2003). The assay was performed as follows: cells were co-
transfected with either 100ng TOP plasmid or 100ng FOP plasmid and 10ng of the CMV-
renilla plasmid. To test the inducibility of the reporter assay, 50ng S33Y-ȕ-catenin plasmid 
was co-transfected as well. In all experiments cells were grown for 24 hours after transfection 
and then lysed using a proprietary lysis buffer (Promega, Mannheim, Germany). Lysates were 
transferred to a 96-well plate, luciferase substrate was added and the luciferase activity was 
measured using a plate reader (Mithras LB940, Berthold Technologies GmbH, Bad Wildbad, 
Germany). After background-subtraction and normalization, relative light units (RLU) were 
divided (TOP divided by FOP) to obtain a signaling activity factors. Each experiment was 
performed in triplicate and independently repeated three times. 
2.9 RNA isolations and PCR 
RNA was isolated using the Qiagen RNA Extraction kit according to the manufacturer’s 
manual. All samples were treated with DNase. To ensure sample purity, only RNA samples 
with 260/280 values around 1.8 were used. PCR reactions were performed in 25µl format; 
each reaction contained cDNA reverse-transcripted from 500ng RNA, SYBR® Green PCR 
Master Mix (Applied Biosystems), dNTPs. DTT and primer mix. The following optimized 
PCR protocol was used: pre-cycling-degradation for 10 min at 95°C, annealing for 0.5 min at 
60°C, elongation for 1 min at 72°C, degradation for 30 sec at 95°C, 40 cycles were run. For 
each PCR experiment, a melting curve measurement was performed to ensure product-
specificity. Primers were designed as exon-spanning and optimized before usage to achieve 
high efficiency and specificity. The resulting cycle threshold (Ct) values were normalized to 
the mean of three housekeeping genes (i.e. HPRT1, YWHAZ and GAPDH). The -ǻǻCT al-
gorithm was applied to analyze the relative changes in gene expression between two cell pop-
ulations (Livak and Schmittgen 2001). 
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2.10 Statistical analysis 
For the statistical analysis of irradiation and cell cycle experiments, a multiple linear regres-
sion model was used. In case of the irradiation experiments, the normalized surviving fraction 
was described as the dependent variable, given the independent variables of irradiation dose, 
group (negative control versus SCC) and replicate pairing (experiments that were performed 
at the same time). In case of the cell cycle analysis, a similar multiple linear regression was 
used to model the percentage of cells in G2/M phase as the dependent variable, given the in-
dependent variables of time-after-radiation, group (negative control versus SCC) and replicate 
pairing. An analysis of variance was performed on these models to identify significant varia-
bles and interaction effects. For all other analyses, an unpaired two-tailed Student’s t-test was 
used.  
For all analyses P-values, <0.05 was considered significant, and P-values <0.001 were con-
sidered highly significant. Data are represented as mean ± standard error of the mean. All 
analyses were performed using the free statistical software R (version 2.9.2). 
3. SUMMARY OF RESULTS 
3.1 TCF7L2 expression is correlated to radioresistance 
In previous studies, our group demonstrated that the transcription factor TCF7L2 was linked 
to resistance to radiation therapy. In 2005 Ghadimi et al. profiled primary rectal cancers that 
were either resistant or sensitive to preoperative chemoradiotherapy, and identified differen-
tially expressed genes. TCF7L2 was one of the genes that were over-expressed in resistant 
tumors, and, in fact, TCF7L2 was one of the most promising targets based on a series of sta-
tistical criteria. The goal of my doctoral thesis was to elucidate the functional relevance of the 
observed overexpression of TCF7L2 in mediating resistance to radiation therapy. 
First, we aimed to recapitulate the respective in-vivo findings made by Ghadimi et al. in an in-
vitro system using established colorectal cancer cells lines. Towards this goal, western blot 
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analyses of eight colorectal cancer cell lines were performed and expression levels of TCF7L2 
were determined (Figure 1A). Next, the expression levels were correlated to the respective 
radiation sensitivities of these cell lines (surviving fraction at 2 Gy of X-Rays, as previously 
reported by Spitzner et al. in 2010). TCF7L2 protein levels were positively correlated to re-
sistance to radiation therapy (Figure 1B; i.e. cells with high TCF7L2 levels are relatively re-
sistant, while cells with low levels are relatively sensitive).  
 
Figure 1 A) Representative western blot analysis of TCF7L2 expression levels in eight colorectal cancer cell 
lines B) Correlation between TCF7L2 expression levels and resistance to radiation measured as survival fraction 
at 2 Gy of X-rays. 
 
These results prompted a more detailed analysis of the relationship of TCF7L2 expression and 
radioresistance. To study whether TCF7L2 is in fact involved in mediating radioresistance, 
loss-of-function experiments using RNA-interference were performed. RNA-interference is a 
molecular mechanism, which uses short RNA molecules to trigger cells to degrade a specific 
mRNA in a sequence-specific manner, ensuring high specificity. For more details and an in-
depth explanation, please refer to the very good review by Rana 2007. 
3.2 Inhibition of TCF7L2 is associated with increased radiosensitivity 
Based on these results, three colorectal cancer cells lines were selected to perform loss-of-
function experiments. Cell lines with both high expression levels of TCF7L2 and high re-
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sistance to radiation were considered to be most suitable. SW837, SW480 and HT-29 best met 
these criteria. Using the Amaxa Nucleofection transfection system, each cell lines was trans-
fected with two different shRNA constructs (referred to as shRNA_1 and shRNA_2 from here 
on). Each vector expresses a shRNA targeting TCF7L2. shRNA (short-hairpin RNA) mole-
cules are constitutively expressed by the host cell and stably silence their target gene using the 
RNA-interference mechanism briefly described above. As a negative control (shNeg), a vec-
tor expressing a “scrambled” shRNA sequence, whose target sequence does not exist in the 
host cell’s DNA, was used. This control is needed to account for cellular changes due to trans-
fection, selection and expression of an artificial RNA sequence. To obtain homogeneous cell 
populations, cells were selected using puromycin-containing medium until only cells express-
ing the shRNA vector remained. At this point, single cell cloning was performed. Once ho-
mogeneous single cell clone populations (SCC) were established, the actual irradiation exper-
iments were performed. Initially, for SW837, five homogeneous SCC populations were 
established from the heterogeneous shRNA_1 population and nine from shRNA_2; for 
SW480, ten from shRNA_1, eleven from shRNA_2; and for HT-29, eleven from shRNA_1, 
and ten from shRNA_2. 
Prior to the irradiation experiments, those SCC populations that showed the most prominent 
downregulation of TCF7L2 were selected for further experimentation. Two populations for 
each vector were chosen, in total 12 cell populations (four per cell line) were used. All popu-
lations showed pronounced reduction of TCF7L2 protein levels compared to the non-
silencing control (Figure 2). 
 
Figure 2: Expression levels of TCF7L2 after RNAi-mediated inhibition using two different shRNA vectors in 
three colorectal cancer cell lines. shNeg served as control.  
 
Summary of results   13 
 
 
Irradiation experiments were performed using irradiation doses of 1, 2, 4, 6 and 8 Gy. De-
pending on cellular growth characteristics, clones were grown for 8 days (HT-29), 10 days 
(SW480) or 21 days (SW837).  
At the indicated time points, colonies with more than 50 cells were counted as “survivor”, i.e. 
cells/colonies which were able to survive the damage induced by irradiation. This procedure 
is standard procedure in radiation oncology, and the number 50 is chosen due to the fact that 
even a cell that was severely damaged by radiation might still be able to divide up to 5 times 
before dying. On the other hand it is very unlikely that a severely damaged cell will divide as 
often as it is needed to form a colony of 50 or more cells (Puck and Marcus 1956). The results 
of the irradiation experiments are shown in figure 3 (representative irradiation curves). 
Compared to the non-silencing control, cells expressing the shTCF7L2 were more severely 
affected by irradiation, i.e. fewer cells survived. A highly significant radiosensitization was 
observed in all SW837 and SW480 SCCs (P < 10-16 and P <10-16, respectively; multiple linear 
regression model), while HT-29 SCCs (P=0.7, multiple linear regression) were not affected at 
all. Since there is no prominent difference in e.g. the mutational setup of these three cell lines 
or any other apparent reason, this clear divergence between SW480 and SW837 on the one 
hand, and HT-29 on the other hand, remained to be explained at this point.  
 
Figure 3  Survival curves for three colorectal cancer cell lines. Curves show survival after 0, 1, 2, 4, 6 and 8 Gy 
of X-rays in one representative shTCF7L2 clone for each cell line and shNeg. 
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The irradiation experiment clearly showed that the inhibition of TCF7L2 causes a distinct 
radiosensitization in at least a subset of colorectal cancer cell lines.  
 
Figure 4 Survival curves for two colorectal cancer cell lines. Curves show survival after combined 5-FU based 
chemoradiotherapy and irradiation at 1, 2, 4, 6 and 8 Gy of X-rays in a representative shTCF7L2 clone and 
shNeg. 
 
As stated above, the standard therapy for locally advanced rectal cancers consists of 5-FU-
based chemoradiotheray. Due to this fact, a treatment regimen combining 3µM of 5-FU fol-
lowed by irradiation was used as well. This setting was tested in SW837 and HT-29. Com-
pared to the radiation-only experiments, very similar results were obtained. Again, HT-29 
wasn’t affected by the inhibition of TCF7L2. Representative curves are shown in figure 4. 
Next, to further understand the reason for the observed radiosensitization and to elucidate the 
difference between the cell lines (i.e., no effect in HT-29), functional downstream experi-
ments were performed. 
3.3 Impaired cell cycle control and reduced DNA damage repair increase 
sensitivity 
Subsequent experiments were performed in SW837, representative of a cell line affected by 
TCF7L2 inhibition, and HT-29, representative of a cell line unaffected by TCF7L2 inhibition. 
Cell cycle distribution at the time of irradiation, cell cycle control after irradiation, and an 
adequate response to DNA damage are important factors determining cellular survival after 
radiation (O'Driscoll and Jeggo 2006). To test whether the observed sensitization is due to an 
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impairment of one or more of these processes, cell cycle and DNA damage response experi-
ments were performed in SW837 and HT-29 SCC populations. 
 
Figure 5 A + B) Cell cycle distribution at the time of irradiation in one representative shRNA clone and shNeg 
control in SW837 and HT-29. C + D) Cell cycle distribution 0, 4, and 8 hours after irradiation in one representa-
tive shRNA clone and shNeg control in SW837 and HT-29. 
 
First, cell cycle distribution at the time of irradiation was studied using flow cytometry (ex-
emplified in Figure 5A). Cells were seeded in parallel to the irradiation experiments to be able 
to directly correlate these results to the irradiation experiments. Compared to the non-
silencing control, an increase in G2/M phase cells was observed in SW837 SCCs (Figure 5B). 
Compared to other cell cycle phases, cells in G2/M phase are more sensitive to irradiation due 
to their higher DNA content (Seiwert et al. 2007), providing an explanation for the observed 
sensitization in the SW837 SCCs. In striking contrast to the SW837 SCCs, and fitting with 
previous results, no change in cell cycle distribution was observed in the HT-29 SCCs. 
Next, the cell’s ability to properly control cell cycle progression after irradiation was studied. 
Physiologically, eukaryotic cells arrest in G2/M phase after radiation damage to allow time 
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for repair of DNA damage, and, importantly, not to progress through mitosis with a persistent 
damage (O'Driscoll and Jeggo 2006). To evaluate whether this control mechanism is affected 
by the inhibition of TCF7L2, cells were seeded and irradiated in parallel to the irradiation 
experiments, and cell cycle distribution was analyzed at 0, 4 and 8 hours after irradiation. In-
deed, an effect on the cell cycle control was observed in the SW837 SCCs compared to the 
non-silencing control (shNeg). In fact, the SW837 SCCs failed to adequately stop cell cycle 
progression after irradiation (Figure 5C), shown as an inadequately increased fraction of cells 
in the G2/M phase after irradiation. HT-29 SCCs did not differ from the non-silencing control 
(Figure 5D). SW837 SCCs continued cycling almost unaffected, providing further evidence 
that important resistance and survival mechanisms are impaired by the inhibition of TCF7L2 
in SW837 SCCs. These result fit nicely with the observation that only the SW837 SCCs were 
sensitized to radiation therapy after inhibition of TCF7L2. 
Next, experiments were performed to study the DNA damage repair response machinery. Suf-
ficient repair of radiation-induced DNA damage, most importantly DNA double strand breaks 
(DSBs), is extremely important for the cell’s ability to survive radiation (Bonner et al. 2008, 
Lobrich et al. 2010). To study the repair of DSBs, the presence and persistence of JH2AX foci 
was monitored. Phosphorylated H2AX proteins accumulate at the site of DNA double strand 
breaks as a part of the signaling cascade leading to the repair of the respective DNA damage 
(Lobrich et al. 2010). For each sample, three measurements were performed: without irradia-
tion (negative control), 15 minutes after irradiation with 2 Gy, and 24 hours after irradiation. 
JH2AX foci were studied 15 minutes after irradiation to ensure that irradiation induced equal 
numbers of foci in all samples (representative microscopy pictures shown in figure 6A and C). 
This is of high importance since the repair rather than the induction of JH2AX foci is corre-
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lated with sensitivity to irradiation (Lobrich et al. 2010). 
 
Figure 6 A + C) ȖH2AX foci measured 0, 15 minutes, and 24 hours after irradiation with 2 Gy of X-rays in one 
representative shRNA clone and shNeg in two cell lines. C + D) Comparison of remaining foci 24 hours after 
irradiation. 
 
It is generally accepted that the persistence of foci 24 hours after irradiation correlates tightly 
with the cell’s ability to sufficiently repair DNA double strand breaks, and, in turn, with re-
sistance to irradiation (Dikomey et al. 1998). In all cell lines and clones induction of JH2AX 
foci was highly similar (induction time point 15 min, figure 6A + C) and statistically not sig-
nificant. The SW837 non-silencing control was able to sufficiently repair damage and almost 
no foci persisted 24 hours after irradiation. In stark contrast, in the SW837 SCCs, most foci 
were still present at this time point, indicating persistent double strand breaks and impaired 
DNA damage repair. As a consequence, this results in an increased sensitivity to radiation, 
i.e., a reduced resistance (Figure 6B). The difference in DNA damage repair provides further 
insights into the cause of radiosensitization observed upon silencing of TCF7L2. HT-29 SCCs 
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did not differ from the respective non-silencing control, and all populations repaired DSBs 
equally well (Figure 6D).  
Taken together, these results fit together nicely (i.e., SW837 is functionally affected by the 
inhibition of TCF7L2 in all experiments, while HT-29 is not) and form a coherent picture. 
However, the exact underlying mechanism for this difference remains to be elucidated. 
3.4 Inhibition only affects active cell lines 
As explained above, TCF7L2 requires, in general (as part of canonical Wnt/ȕ-catenin signal-
ing), activated ȕ-catenin to be transcriptional active, and in fact the expression levels of 
TCF7L2 alone do not necessarily predict the level of transcriptional activity (Moon et al. 
2004). The following hypothesis was put forward: not the expression level of TCF7L2 (as 
described above, all cell lines express very similar levels), but rather the transcriptional activi-
ty is responsible for the observed differences between SW837 and HT-29. To test this hy-
pothesis, a TCF reporter assay was used to measure baseline levels and inducibility of TCF 
transcriptional activity.  
 
Figure 7 A) Baseline and induced TCF7L2 reporter activity measured using the TOPFLAHS/FOPFLASH re-
porter assay B) Comparison of cytosolic and nuclear active ȕ-catenin in three colorectal cancer cell lines. 
 
As expected, SW837 wild type cells showed prominent baseline reporter activity and pro-
nounced inducibility (4.9-fold over baseline activity), indicative of high transcriptional activi-
ty. HT-29 wild type cells on the other hand showed only minor reporter activity, and only a 
slight increase in activity was observed after co-transfection of mutated ȕ-catenin (Figure 
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7A). To understand this difference in more detail, nuclear (representing the transcriptionally 
active form) and cytosolic (inactive) protein levels of ȕ-catenin were compared separately in 
SW837 and HT-29 wild type cells by western blotting (ȕ-catenin levels were studied in more 
details since, as described above, TCF7L2 expression levels were comparable in SW837 and 
HT-29). Similar nuclear and cytosolic levels were observed in both cell lines, suggesting that 
the observed effects are independent of ȕ-catenin and rely on the transcriptional activity of 
TCF7L2 (Figure 7B). 
3.5 shTCF7L2 deregulates Wnt/TCF7L2 signaling 
As explained above, TCF7L2 is the main transcription factor of canonical Wnt signaling, and 
regulates the transcription of a plethora of downstream genes (Ravindranath et al. 2008). To 
demonstrate that silencing of TCF7L2 results in a transcriptional deregulation of 
Wnt/TCF7L2 signaling in SW837, but not in HT-29, the expression levels of select TCF7L2 
target genes were measured (He et al. 1998, Niida et al. 2004, Tetsu and McCormick 1999). 
Using real-time PCR, a considerable deregulation of several important target genes was ob-
served: CCND1, DKK1 and MYC were deregulated in SW837, with average fold-changes of 
2.4 (CCND1, up-regulated following silencing of TCF7L2), 18.4 (DKK1, down-regulated) 
and 2.7 (MYC, down-regulated). Notably, in HT-29, these downstream target genes either 
showed no prominent deregulation (CCND1) or their deregulation was inconsistent (DKK 
and MYC). The respective levels of deregulation are shown in figure 8.  
Collectively, these results demonstrate that RNAi against TCF7L2 resulted in a transcriptional 
deregulation of Wnt/TCF7L2 signaling in SW837, which was associated with a significant 
sensitization to clinically relevant doses of X-rays. Again, HT-29 was not affected by the in-
hibition of TCF7L2. Further work is warranted to fully understand the relevance of the regula-
tion of TCF7L2 target genes and the underlying mechanism causing the observed sensitiza-
tion 




Figure 8 Transcriptional deregulation of three Wnt/TCF7L2 target genes measured in four shRNA clones each in 
two colorectal cancer cell lines. 
 
4. SUMMARY AND CONCLUSION 
In this doctoral thesis, the effects of TCF7L2 mediating resistance to irradiation were studied. 
Previously, gene expression signatures of primary rectal cancers, classified as either resistant 
or sensitive to pre-operative (chemo-) radiotherapy, were compared, and TCF7L2 was found 
to be significantly overexpressed in the resistant tumors (Ghadimi et al. 2005). Consequently, 
TCF7L2 was considered a promising target gene to sensitize a priori resistant tumors. Here, 
the functional relevance of TCF7L2 for mediating radioresistance in an in-vitro setting was 
elucidated. TCF7L2 protein expression was positively correlated with resistance to irradiation 
and its RNA-mediated silencing led to a significant (chemo-)radiosensitization in SW837 and 
SW480 cells, whereas HT-29 cells were not sensitized at all. Sensitization in SW837 
(TCF7L2-signaling active cell line) was a consequence of functional changes in cell cycle 
distribution, impaired cell cycle control, and impaired DNA damage response. HT-29 SCCs 
(TCF7L2-signaling inactive cell line) did not show any functional changes after inhibition of 
TCF7L2. All results coherently point to the fact that HT-29 cells apparently do not need 
TCF7L2 for mediating resistance to irradiation and are therefore not impacted by its inhibi-
tion. SW837 cells on the other hand need TCF7L2 and are severely affected by the inhibition 
of its transcription program, causing a pronounced sensitization.  
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In conclusion, TCF7L2 was identified as functionally relevant for mediating resistance of 
colorectal cancer cells to (chemo-)radiotherapy with potential significance for future treat-
ment options, e.g. targeting TCF7L2 prior to (chemo-)radiotherapy. Furthermore, these data 
suggest that only cell lines with active Wnt/TCF signaling are sensitized upon silencing of 
TCF7L2, providing a possible way to stratify tumors in the future, and to make treatment de-
cisions based on the activity of this pathway. Finally, these results functionally link the Wnt 
signaling pathway to resistance to (chemo-)radiotherapy in colorectal cancer, which repre-
sents a novel finding. These results have been published in 2011 in Carcinogenesis.  
 
Figure 9 A) Mechanistic model for the novel role of Wnt/TCF7L2 signaling in sensitization after TFC7L2 si-
lencing. B) Potential pre-operative treatment stratification based on Wnt/TCF7L2 activity. 
 
Figure 9A summarizes the main results of this study and proposes a potential algorithm for 
stratification of primary rectal cancers based on the activity of the Wnt/ȕ-catenin/TCF7L2 
signaling pathway (Figure 9B).  
5. OUTLOOK 
Since the Wnt/ȕ-catenin pathway and TCF7L2 signaling are extremely complex, several ques-
tions remain to be answered in future studies. While these experiments indicate that the ob-
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served sensitization is independent of ȕ-catenin, the precise role of ȕ-catenin in mediating 
resistance remains to be elucidated. RNA interference experiments targeting ȕ-catenin and 
other members of the Wnt signaling cascade  might help to understand in detail if TCF7L2 
signaling is indeed the only factor required for chemoradiosensitization or if resistance is an 
result of a more complex interaction.  
Furthermore, the exact mechanism of sensitization is not yet understood, i.e. which set of 
TCF7L2 downstream targets directly mediates the sensitization effect. Gene expression mi-
croarray analyses before and after silencing of TCF7L2 might provide valuable insights and a 
set of potentially relevant target genes to study in functional experiments. 
Finally, experiments using xenograft models are warranted to replicate these observations in 
an in-vivo setting, and to take the first step towards implementing these results in a clinical 
setting.  
ȕ-catenin knockdown experiments and xenograft experiments in mice are currently being 
conducted. 
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A considerable percentage of rectal cancers are resistant to stan-
dard preoperative chemoradiotherapy. Because patients with
a priori-resistant tumors do not benefit from multimodal treat-
ment, understanding and overcoming this resistance remains of
utmost clinical importance. We recently reported overexpression
of the Wnt transcription factor TCF4, also known as TCF7L2, in
rectal cancers that were resistant to 5-fluorouracil-based chemo-
radiotherapy. Because Wnt signaling has not been associated with
treatment response, we aimed to investigate whether TCF4 medi-
ates chemoradioresistance. RNA interference-mediated silencing
of TCF4 was employed in three colorectal cancer (CRC) cell lines,
and sensitivity to (chemo-) radiotherapy was assessed using a stan-
dard colony formation assay. Silencing of TCF4 caused a signifi-
cant sensitization of CRC cells to clinically relevant doses of
X-rays. This effect was restricted to tumor cells with high T cell
factor (TCF) reporter activity, presumably in a b-catenin-inde-
pendent manner. Radiosensitization was the consequence of (i)
a transcriptional deregulation of Wnt/TCF4 target genes, (ii) a si-
lencing-induced G2/M phase arrest, (iii) an impaired ability to
adequately halt cell cycle progression after radiation and (iv)
a compromised DNA double strand break repair as assessed by
gH2AX staining. Taken together, our results indicate a novel
mechanism through which the Wnt transcription factor TCF4
mediates chemoradioresistance. Moreover, they suggest that
TCF4 is a promising molecular target to sensitize resistant tumor
cells to (chemo-) radiotherapy.
Introduction
The standard treatment for locally advanced rectal cancers consists of
preoperative 5-fluorouracil (5-FU)-based chemoradiotherapy fol-
lowed by radical surgery (1). This multimodal approach reduces local
recurrence (2). However, clinical response to chemoradiotherapy
varies greatly, and a considerable percentage of rectal cancers are
chemoradioresistant, even if intensified regimens are being pursued
(3). This represents a substantial clinical and socioeconomic problem.
Thus, it is of utmost clinical importance to determine the molecular
characteristics underlying this resistance and to identify effective
strategies to overcome it (4). Previously, we have therefore used gene
expression profiling of resistant and responsive rectal cancers from
patients who had been treated with preoperative chemoradiotherapy
within a phase III clinical trial (2) and found TCF4 to be significantly
overexpressed in resistant tumors (5).
T cell factor 4 (TCF4), also known as TCF7L2, represents a key
transcription factor that mediates canonical Wnt signaling, which
plays a central role in embryonic development and in the maintenance
of tissue homeostasis (6–8). Binding of Wnt ligands to cell surface
receptors of the Frizzled family inhibits glycogen synthase kinase-3b-
mediated phosphorylation of the cotranscription factor b-catenin,
leading to its stabilization and subsequent accumulation in the nu-
cleus. This results in binding to members of the TCF and lymphoid
enhancer-binding factor family of transcription factors (9), which in
turn induces or represses transcription of a plethora of target genes
(http://www.stanford.edu/group/nusselab/cgi-bin/wnt/).
Although aberrant Wnt signaling promotes colorectal cancer (CRC)
development (6–8), it has not yet been associated with treatment
resistance. In the present study, we therefore tested whether the ob-
served overexpression of TCF4 is of functional relevance for mediating
chemoradioresistance in rectal cancer.
Materials and methods
Cell culture
Human CRC cell lines Caco-2, HT-29, SW1116, SW1463, SW480, SW620,
SW837 and WiDr were obtained from the American Type Culture Collection
(ATCC, Manassas, VA) and cultured as described recently (10). Cell line
identity has been confirmed by short tandem repeat profiling (10), and absence
of Mycoplasma contamination was tested periodically by polymerase chain
reaction (PCR).
Establishment of stable single-cell clone populations
Individual Expression ArrestTM lentiviral short-hairpin RNA constructs target-
ing TCF4, and a non-silencing control shRNA (shNeg), were obtained from
Open Biosystems (Thermo Fisher Scientific, Huntsville, AL). The respective
target sequences are listed in Supplementary Table S1, available at Carcino-
genesis Online. As described recently (11), cells grown in log phase were
transfected at 60–70% confluence with 2.5 lg of linearized vector DNA using
theAmaxaNucleofector System (Lonza, Cologne,Germany), and stable single-
cell clone (SCC) populations were subsequently established.
Western blotting
Cells were lysed in a lysis buffer containing 1% NP-40 and protease and
phosphatase inhibitor cocktail. To separate cytosolic and nuclear fraction, cells
were lysed using two separate lysis buffers containing 0.5% and 1% NP-40,
respectively, and a protease and phosphatase inhibitor cocktail. Blocking was
performed using 5% blotting grade milk. Membranes were probed overnight at
4!C with a rabbit anti-TCF4 antibody (1:10 000; Abcam, Cambridge, UK) or
a mouse anti-b-catenin antibody (1:2000; Santa Cruz Biotechnology, Heidelberg,
Germany) followed by a mouse anti-active-b-catenin antibody (1:2000; Milli-
pore, Schwalbach, Germany). To confirm successful nuclear protein extraction,
a rabbit anti-HDAC1 antibody was used (1:1000; New England Biolabs GmbH,
Frankfurt am Main, Germany). Equal loading was ensured using a rabbit anti-
actin antibody (1:2000; Sigma–Aldrich, Steinheim, Germany). As secondary
antibody, either a goat anti-rabbit or a rabbit anti-mouse peroxidase linked anti-
body (both 1:30 000; Acris Antibodies, Herford, Germany) was used. Membranes
were developed using an enhanced chemiluminescence detection system (ECL
Advanced, GE Healthcare, Buckinghamshire, UK) and signals were detected
using a CCD-Camera (LAS-3000 Imager; Fuji-Film, Düsseldorf, Germany).
The optical density was measured using the ImageJ software (NIH).
Irradiation and determination of cell survival
Tumor cells growing in log phase were seeded as single-cell suspensions into
six-well plates and allowed to adhere overnight. Subsequently, cells were
irradiated with a single dose of 1, 2, 4, 6 and 8 Gy of X-rays (Gulmay Medical
Ltd, Camberley, UK), and a standard colony-forming assay was performed to
determine the respective surviving fractions. After defined time periods (Sup-
plementary Table S2 is available at Carcinogenesis Online), cells were fixed
with 70% ethanol and stained. Colonies with .50 cells were scored as survi-
vors. Non-irradiated cultures were used for data normalization. Experiments
Abbreviations: CRC, colorectal cancer; 5-FU, 5-fluorouracil; PCR, polymer-
ase chain reaction; SCC, single-cell clone; TCF, T cell factor.
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were performed as technical triplicates and independently repeated three times.
To estimate the sensitivity to chemoradiotherapy, cells were exposed to 3 lM
of 5-FU (Sigma–Aldrich) for 16 h before irradiation, as described recently
(10). Calculation of survival fractions (SF) was done using the equation
SF # colonies counted/cells seeded $ (plating efficiency/100). Survival
variables a and b were fitted according to the linear quadratic equation.
Dose-modifying factors at 37% survival and survival variables a and b have
been calculated using KaleidaGraph (Synergy Software, Reading, PA) and are
shown in Supplementary Table S3, available at Carcinogenesis Online.
Cell cycle analysis
Cell cycle distribution was analyzed before, and 4 and 8 h after irradiation at 4
Gy. Cell membranes were permeabilized at #20!C overnight using 70% meth-
anol. Subsequently, cells were treated with 10 lg/ml RNase A (Qiagen, Hilden,
Germany) for 30 min at 37!C and stained with 20 ll/ml propidium iodide
(Sigma–Aldrich) for 20 min at 37!C. DNA content was measured by flow
cytometry (FACScan; BDBioscience, Heidelberg, Germany) and analyzed using
the FlowJo software package (Tree Star, Ashland, OR).
Immunofluorescence and quantification of phosphorylated histone H2AX foci
formation
Cells were seeded onto microscope slides and allowed to adhere overnight.
Sixteen hours later, slides were irradiated at 2 Gy and fixed with 2% formal-
dehyde/phosphate-buffered saline for 15 min. Cells were permeabilized with
0.2% Triton X-100/phosphate-buffered saline/1% fetal bovine serum for 10
min on ice and blocked with 5% bovine serum albumin/1% fetal bovine serum/
phosphate-buffered saline. Slides were incubated with a mouse anti-phospho-
histone H2AX antibody (1:1000; Millipore) over night at 4!C, followed by
incubation with a fluorescence-coupled mouse anti-rabbit secondary antibody
(1:400; Alexa Fluor 594, Molecular Probes/Invitrogen, Darmstadt, Germany).
Nuclei were counterstained with 4#,6-diamidino-2-phenylindole (Sigma–
Aldrich) andmounted usingVECTASHIELD (Vector Laboratories, Peterborough,
UK). Radiation-induced cH2AX foci were counted in at least 100 cells per sample
using a fluorescence microscope (DM6000; Leica, Wetzlar, Germany) and the
Leica Application Suite.
TOP-FLASH/FOP-FLASH dual luciferase reporter assay
Cells were transfected with 100 ng TOP-FLASH plasmid containing six TCF-
binding motifs (Millipore) or 100 ng FOP-FLASH control plasmid containing
six-mutated TCF-binding motifs (Millipore). Each sample was cotransfected
with 10 ng renilla luciferase plasmid (pRL-CMV; Promega, Mannheim, Ger-
many) to normalize for cell viability and transfection efficiency. To estimate
the inducibility of TCF reporter activity, cells were transfected with 100 ng of
mutated b-catenin (S33Y; Millipore). This mutated protein cannot be inacti-
vated by the degradation complex and translocates to the nucleus, where, after
binding to TCFs, it leads to continuous reporter activity. Cell lysates were
prepared using the Dual Luciferase Lysis Buffer (Promega), and luciferase
activity was measured using a microplate reader (Mithras LB940; Berthold
Technologies GmbH, Bad Wildbad, Germany). Promoter activity was calcu-
lated by dividing relative light units of specific TOP-FLASH and relative light
units of non-specific FOP-FLASH.
Real-time PCR
Real-time PCR was performed as described recently (10), and the correspond-
ing primer sequences can be found in Supplementary Table S4, available at
CarcinogenesisOnline. The resulting cycle threshold (Ct) values were normal-
ized according to the mean of three housekeeping genes (i.e. HPRT1, YWHAZ
andGAPDH) and the 2#DDCTalgorithm (12) was applied to analyze the relative
changes in gene expression between two cell populations.
Statistical analysis
A multiple linear regression model was used to describe the normalized sur-
viving fraction as dependent variable, given the independent variables of irra-
diation dose, group (negative control versus SCC) and replicate pairing. A
similar multiple linear regression was used to model the percentage of cells
in G2/M phase as dependent variable, given the independent variables of time-
after-radiation, group (negative control versus SCC) and replicate pairing. An
analysis of variance was performed on these models to reveal significant var-
iables and interaction effects. For all other analyses, an unpaired two-tailed
Student’s t-test was used. P-values ,0.05 were considered significant, and P-
values,0.001 were considered highly significant. Data are expressed as mean
± standard error of the mean. All analyses were performed using the free
statistical software R (version 2.9.2).
Results
TCF4 expression correlates with chemoradioresistance in primary
rectal cancers and in CRC cell lines
Gene expression profiling of primary rectal cancers showed that the
Wnt transcription factor TCF4 was significantly overexpressed in
those tumors that were resistant to preoperative 5-FU-based chemo-
radiotherapy (5). To test whether we can recapitulate these findings
in vitro, we first measured TCF4 protein expression levels in CRC cell
lines (Supplementary Figure S1A is available at Carcinogenesis
Online). We then compared these expression levels with the respective
in vitro sensitivities of these cell lines to 5-FU-based chemoradiother-
apy, which we recently reported (10) and could confirm that elevated
TCF4 expression was positively correlated with resistance to in vitro
chemoradiotherapy (Supplementary Figure S1B is available at
Carcinogenesis Online).
Silencing of TCF4 sensitizes CRC cell lines to irradiation
To test whether the observed overexpression of TCF4 is functionally
relevant for treatment resistance, RNAi-mediated silencing was em-
ployed in three p53-mutant CRC cell lines (13,14) that expressed high
levels of TCF4, i.e. SW837, HT-29 and SW480, using two short-hairpin
RNA constructs. Stable SCC populations were established, and two
SCCs from each vector were selected for further experimentation. Suc-
cessful RNAi-mediated silencing of TCF4 was demonstrated using
western blot analysis (Figure 1A).
Subsequently, selected SCC populations were irradiated at clini-
cally relevant doses of X-rays, and the respective surviving fractions
were measured using a standard colony-forming assay. Compared
with the non-silencing control shRNA, silencing of TCF4 signifi-
cantly increased sensitivity of all SW837 and SW480 SCCs to radi-
ation (P , 10#16 and P , 10#16, respectively; multiple linear
regression model). In clear contrast, TCF4 silencing had no effect
on HT-29 cells (P 5 0.7; Figure 1B, Supplementary Figure S2 is
available at Carcinogenesis Online). Survival variables a and b and
dose modulation factors are shown in Supplementary Table S3, avail-
able at Carcinogenesis Online. Notably, in SW837 and SW480, TCF4
protein expression levels increased in response to treatment with 6 Gy
of X-rays, whereas the expression of TCF4 was unchanged in HT-29
(Supplementary Figure S3 is available at Carcinogenesis Online).
Because the standard therapy for locally advanced rectal cancers
comprises 5-FU-based chemoradiotherapy, we also employed a combi-
nation of 3 lM of 5-FU and irradiation, as recently described (10) and
observed very similar results. RNAi against TCF4 sensitized SW837
SCCs, but not HT-29 SCCs (Supplementary Figure S4 is available at
Carcinogenesis Online).
Silencing of TCF4 induces accumulation of SW837 cells in G2/M
phase
Next, we investigated the cellular processes leading to the significant
radiosensitization of SW837 SCCs. These and other follow-up experi-
ments were performed exclusively in SW837 and HT-29. These two
lines were chosen because both are highly chemoradioresistant, and
we wanted to analyze the phenotype of resistance and sensitization,
respectively.
Cells are not equally sensitive to radiation throughout the cell cycle
but show increased radiation sensitivity in G2/M (15). We therefore
performed cell cycle analyses of unirradiated SW837 and HT-29 SCC
populations (exemplified in Figure 2A). Regarding SW837, an aver-
age of 23% of cells from different SCCs were captured in the G2/M
phase compared with only 15% of cells from the non-silencing control
(Figure 2B). This difference was statistically significant (P , 0.01)
and suggests that radiosensitization of SW837 SCCs is at least in part
attributable to an accumulation of cells in radiosensitive phases of the
cell cycle (15). In clear contrast, no significant changes in cell cycle
distribution were detected between HT-29 SCCs and the respective
non-silencing control (Figure 2A and B).
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Silencing of TCF4 impairs radiation-induced G2/M arrest in SW837
Radiation exposure of eukaryotic cells results in a cell cycle delay
required for DNA damage repair or induction of apoptosis (16). We
therefore tested whether silencing of TCF4 leads to impaired cell
cycle control after radiation as reflected by a lack of accumulation
in G2/M phase. In the SW837 non-silencing control, the fraction of
cells in G2/M phase markedly increased from 15% at the time of
radiation to 36% 8 h after radiation (Figure 2C). In contrast, we only
observed a slight increase in SW837 SCCs from 23 to 30% (Figure 2C).
This difference in cell cycle control, i.e. changes in the cell cycle
distribution over time, was statistically significant (P, 0.05) between
the negative control and the respective SCC populations in SW837. In
HT-29, however, silencing of TCF4 did not alter cell cycle progres-
sion, i.e. both populations (SCCs and control) adequately arrested in
G2/M phase 8 h after radiation (Figure 2D), corresponding to a lack of
radiosensitization.
Silencing of TCF4 impairs DNA double strand break repair in SW837
Insufficient DNA damage repair is an important component of radi-
ation-induced cell killing (17,18). To determine whether the radio-
sensitization following RNAi against TCF4 is indeed attributable to
impaired DNA damage repair, we monitored the presence and persis-
tence of phosphorylated histone H2AX (cH2AX) foci (17,18).
Regarding SW837, both populations (shNeg and SCCs) showed very
few cH2AX foci in unirradiated cells and comparable levels of foci
induction 15 min after irradiation at 2 Gy (exemplified in Figure 3A).
Importantly, however, 24 h after irradiation, few foci remained in the
non-silencing control, whereas the number of cH2AX foci in SW837
SCCs persisted at considerably higher levels (Figure 3A). This differ-
ence was statistically highly significant (P , 0.001; Figure 3B). These
foci can be considered ‘residual’, pointing to incomplete DNA double
strand break (DSB) repair, which results in radiosensitivity (19,20).
With respect to HT-29, both populations (shNeg and SCCs) showed
minimal cH2AX foci in unirradiated cells and similar induction of
foci 15 min after irradiation at 2 Gy (exemplified in Figure 3C). In
striking contrast to SW837, both HT-29 populations exhibited an
equally low number of cH2AX foci 24 h after irradiation (Figure
3C and D). These data support the notion that silencing of TCF4 leads
to a significant impairment of DNA DSB repair in SW837, but not in
HT-29.
TCF reporter activity determines radiosensitization in a b-catenin
independent manner
TCF4 is a key transcription factor of canonical Wnt signaling (6–9).
We therefore speculated that, despite comparable baseline protein
expression levels of TCF4 in SW837 and HT-29, differences in the
transcriptional activity might have caused the heterogeneous sensitiv-
ity of these cell lines to irradiation upon exposure to RNAi against
TCF4. Using the TOP-FLASH/FOP-FLASH reporter assay, we estab-
lished higher basal reporter activity for wild-type SW837 cells (TOP/
FOP: 6.9) than for wild-type HT-29 cells (TOP/FOP: 1.6). This dif-
ference was statistically significant (P , 0.01; Figure 4A).
TCF4 is a binding partner of b-catenin, as both mediate the effects
of canonical Wnt signaling. Notably, overexpression of mutated
b-catenin (S33Y), which activates TCFs but cannot be inactivated,
caused a .10-fold higher increase in reporter activity in wild-type
SW837 cells (TOP/FOP: 34.3) than in wild-type HT-29 cells (TOP/
FOP: 2.9; P , 0.001).
Next, we analyzed the nuclear and cytosolic levels of b-catenin.
Wild-type SW837 and HT-29 cells exhibited similar protein levels of
both nuclear and cytosolic b-catenin (Figure 4B). These results sug-
gest that radiosensitization following silencing of TCF4 is determined
by TCF transcriptional activity but independent of b-catenin activity.
Deregulation of Wnt/TCF4 signaling in SW837
Finally, to demonstrate that silencing of TCF4 results in a transcrip-
tional deregulation of Wnt/TCF4 signaling in SW837, but not in HT-
29, we measured the expression levels of selected target genes (21–
23). Using real-time PCR, we observed a considerable deregulation of
CCND1, DKK1 and MYC in SW837 (Figure 5), with average fold-
changes of 2.4 (CCND1, upregulated following silencing of TCF4),
18.4 (DKK1, downregulated) and 2.7 (MYC, downregulated). Notably,
in HT-29, these downstream target genes either showed no prominent
deregulation (CCND1; Figure 5) or their deregulation was inconsis-
tent compared with SW837 (DKK and MYC; Figure 5). Collectively,
these results demonstrate that RNAi against TCF4 resulted in a tran-
scriptional deregulation of Wnt/TCF4 signaling in SW837, which was
Fig. 1. Silencing of TCF4 sensitizes SW837 and SW480 to radiation. (A) Cell lines were transfected with two individual shRNA constructs targeting TCF4 and
stable SCC populations were established. Compared with a non-silencing control shRNA (shNeg), all clones exhibited markedly reduced protein levels of TCF4.
(B) Selected SCCs were irradiated at clinically relevant doses of X-rays. A standard colony-forming assay demonstrated that silencing of TCF4 significantly
increased the radiosensitivity of SW480 and SW837 but not of HT-29 (exemplified for one representative SCC per cell line; see also Supplementary Figure S2,
available at Carcinogenesis Online). Data are presented as mean of three independent experiments ± standard error of the mean.
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associated with a significant sensitization to clinically relevant doses
of X-rays.
Discussion
Resistance to preoperative chemoradiotherapy represents a major clin-
ical problem in the treatment of rectal cancer. Consequently, the iden-
tification of novel therapeutic targets whose modification could be
harnessed to sensitize a priori-resistant tumors to radiation is exceed-
ingly important. Our earlier studies showed that the Wnt transcription
factor TCF4 was overexpressed in primary rectal cancers that were
resistant to preoperative chemoradiotherapy (5). The fact that Wnt
signaling has not been previously associated with treatment resistance
prompted us to explorewhether this finding is functionally relevant. We
now report that the Wnt transcription factor TCF4 mediates resistance
to treatment with (chemo-) radiotherapy.
We first observed that TCF4 expression levels also correlated with
(chemo-) radioresistance in CRC cell lines (Supplementary Figure
S1B is available at Carcinogenesis Online). In order to explore the
mechanistic basis of this correlation, we silenced TCF4 using RNA
interference and measured the phenotypic effects. Indeed, silencing of
TCF4 considerably increased sensitivity of SW480 and SW837 to
clinically relevant doses of X-rays (Figure 1B, Supplementary Figure
S2 is available at CarcinogenesisOnline). However, this response was
not uniform: the cell line HT-29 remained at resistance levels ob-
served before silencing TCF4. A similar divergence became apparent
when wild-type cell lines were treated with irradiation. In SW837 and
SW480, TCF4 protein expression levels increased in response to
treatment with 6 Gy of X-rays, whereas the expression of TCF4
was unchanged in HT-29 (Supplementary Figure S3 is available at
Carcinogenesis Online). This suggests that TCF4 plays different roles
in these cell lines in mediating the response to irradiation.
To further clarify the functional mechanism of this increased sen-
sitivity of SW837 after TCF4 depletion, we performed cell cycle
measurements. Silencing of TCF4 was paralleled by an increased
fraction of cells in the G2/M phase of the cell cycle at the time of
irradiation (0 h; Figure 2A and B). This phase is known for increased
vulnerability to radiation-induced DNA damage (15). Of note, there
was no change in cell cycle distribution upon silencing of TCF4 in
HT-29, entirely consistent with its unchanged radiation response.
Exposure of cells to radiation per se leads to an arrest of cells in G2/
M phase, allowing time for DNA damage repair (16). In SW837,
however, the G2/M arrest after irradiation (4 and 8 h) was significantly
less pronounced after silencing of TCF4 (Figure 2C). This impaired
ability of the SW837 SCCs to halt cell cycle progression after irradi-
ation was associated with a high number of persisting cH2AX foci
(Figure 3A and B), which accumulate at sites of unrepaired DNA (17).
These residual foci in SW837 SCCs suggest a compromised DNA
DSB repair as an explanation for the increased radiosensitivity
(19,20). In other words, these SCCs may re-enter the cell cycle with
persistent DNA DSBs, which would be consistent with an increased
radiosensitivity (24,25). In contrast, radiation-induced cell cycle ar-
rest was not affected by silencing of TCF4 in HT-29 (Figure 2D), and
the amount of cH2AX foci returned to near baseline levels after 24 h
Fig. 2. Silencing of TCF4 in SW837 induces a G2/M arrest and impairs cell cycle control after radiation. (A) Representative cell cycle analysis of unirradiated
tumor cells. (B) Compared with the non-silencing control, unirradiated SW837 SCCs exhibited a significantly higher fraction of cells in the radiosensitive G2/M
phase (P, 0.01), whereas silencing of TCF4 in HT-29 did not alter cell cycle distribution. There was no difference in cell cycle distribution/progression between
unirradiated shTCF4 SCCs and the respective non-silencing controls (data not shown). (C) Cell cycle analyses were also performed after irradiation. In the SW837
non-silencing control, the fraction of cells in G2/M phase significantly increased 4 and 8 h after irradiation at 4 Gy (P, 0.05). In contrast, there was only a slight
increase in SW837 SCCs, indicating an impaired ability of these SCCs to adequately halt cell cycle progression after irradiation. (D) Irradiation of both non-
silencing control and SCCs in HT-29 did not alter cell cycle progression. Data are presented as mean of at least three independent experiments ± standard error of
the mean.
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regardless of the presence of TCF4 (Figure 3C and D). Taken together,
TCF4 seems to play an important role in regulating both cell cycle and
DNA damage repair in a subset of CRC cells.
It is important to note that although connections between Wnt
signaling and cell cycle regulation have been postulated (26,27), only
limited mechanistic details in support of the interplay between the two
processes have been reported (26,27). Interestingly, van de Wetering
et al. (28) previously observed that inhibition of TCF4 activity in
LS174T (wild-type p53 protein) and in DLD-1 (mutant p53 protein)
using overexpression of a dominant-negative TCF4 protein mediated
a G1 arrest. This discrepancy with our observations could have been
because of two reasons. Firstly, these authors have used a method
that completely diminishes TCF4 protein levels, whereas, in our ex-
periments, up to 10–20% of TCF4 protein remained following RNAi
Fig. 3. Impaired radiation-induced DNA DSB repair in SW837 as indicator of increased radiosensitivity. (A) Representative experiment for SW837. Both
populations (negative control and SCC) showed very few phosphorylated histone H2AX (cH2AX) foci at the time of radiation and comparable induction of foci 15
min after irradiation at 2 Gy. Twenty-four hours after irradiation, multiple cH2AX foci were present in the SCCs, whereas considerably fewer foci remained in the
non-silencing control. (B) On average, there were highly significantly more cH2AX foci in SW837 SCCs 24 h after irradiation compared with shNeg (P, 0.001).
(C) Representative experiment for HT-29. Both populations (negative control and SCC) showed very few cH2AX foci at the time of radiation, and exhibited
a comparable induction of foci 15 min and 24 h after after irradiation at 2 Gy. (D) In stark contrast to SW837, there was a similar level of cH2AX foci in negative
control and HT-29 SCCs 24 h after irradiation. Data are presented as mean of three independent experiments ± standard error of the mean.
Fig. 4. Transcriptional activity of TCF determines radioresistance in SW837 in a b-catenin independent manner. (A) Normalized luciferase measurements. We
established higher basal TCF reporter activity for wild-type SW837 cells (specific TOP-FLASH over non-specific FOP-FLASH activity: 6.9) than for wild-type
HT-29 cells (TOP/FOP: 1.6; P , 0.01). Overexpression of mutated b-catenin (S33Y), which binds to TCFs and cannot be inactivated, caused a .10-fold higher
increase in reporter activity in SW837 (TOP/FOP: 34.3) than HT-29 (TOP/FOP: 2.9; P, 0.001). Data are presented as mean of three independent experiments ±
standard error of the mean. (B) Based on western blot analysis, SW837 and HT-29 show comparable nuclear and cytosolic expression levels of both active
(phosphorylated) and total b-catenin.
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exposure (Figure 1A). Secondly, van de Wetering et al. analyzed CRC
cell lines that were mismatch repair deficient. Nevertheless, our ob-
servation that RNAi against TCF4 resulted in significant changes in
cell cycle distribution and an impaired ability to adequately halt cell
cycle progression in response to irradiation adds weight to the grow-
ing body of evidence that the cell cycle machinery and Wnt signaling
are functionally linked.
TCF4 represents a key downstream effector of canonical Wnt sig-
naling (6–8). We therefore speculated that the diverse responses of
SW837 and HT-29 may depend on varying transcriptional activities of
TCF4. Indeed, unstimulated baseline levels of TCF reporter activity
were higher in SW837 compared with HT-29 (Figure 4A). Moreover,
reporter activity in SW837 increased dramatically upon overexpres-
sion of a mutated b-catenin protein (S33Y), which leads to constitu-
tive TCF/b-catenin activity, while there was only a slight increase in
HT-29 (Figure 4A). At first glance, these results would indicate that
SW837 is much more responsive to b-catenin binding than HT-29.
Interestingly, however, we observed comparable nuclear and cyto-
solic levels of b-catenin in SW837 and HT-29 (Figure 4B), suggest-
ing that the observed effect is b-catenin independent. In this context,
recent observations demonstrate that lymphoid enhancer-binding
factor/TCF family members do not exclusively confer canonical
Wnt/b-catenin signaling but also function as transcription factors
in an alternative, b-catenin independent manner (29–32), and, pre-
sumably, in b-catenin-independent Wnt signaling (33–35).
Finally, we observed a transcriptional deregulation of the Wnt/
TCF4 target genes CCND1, DKK1 and MYC in SW837 SCCs, but
not in HT-29 SCCs (Figure 5). Surprisingly, DKK1 expression de-
creased upon silencing of TCF4 in SW837 (Figure 5). At a first
glance, this seems counterintuitive because DKK1, a putative Wnt
antagonist, represents a tumor suppressor gene (36). The same holds
true for the observed upregulation of CCDN1. Cyclin D1 represents
a core component of the cell cycle machinery (37,38) and has been
very recently implicated in DNA repair (39). Considering the in-
creased fraction of SW837 cells in G2/M phase following RNAi
against TCF4, this upregulation is unexpected and may be attributed
to the fact that stable SCC populations have been used in this study.
These clones have been cultured for longer periods of time, poten-
tially allowing time to counterbalance certain consequences of dimin-
ished expression of the transcription factor TCF4. Nevertheless, the
transcriptional deregulation of Wnt signaling, irrespective of the di-
rectionality of deregulation, is consistent with the prevailing interpre-
tation that disturbing the net cellular homeostasis of the Wnt pathway
constitutes a critical step toward a tumor promoting function (40).
Although we are the first to report that inhibition of Wnt/TCF4
signaling sensitizes CRC cell lines to radiation and chemoradiother-
apy, preliminary evidence from other model systems is consistent with
these findings. Firstly, our own group recently reported that Wnt
signaling pathway genes were significantly over-represented within
a gene expression signature for in vitro sensitivity of CRC cells lines
to 5-FU-based chemoradiotherapy (10). Secondly, based on the fact
that Wnt signaling has been implicated in regulating the behavior of
both somatic stem cells and tumor-initiating ‘cancer stem’ cells
(41,42), other authors demonstrated that Wnt signaling mediates ra-
diation resistance of mammary progenitor cells in mice (43,44).
Thirdly, Flahaut et al. (45) reported that the frizzled-1 Wnt receptor
FZD1 mediates chemoresistance in neuroblastoma cell lines through
MDR1, whereas Shou et al. observed that overexpression of DKK1
sensitized brain tumor cells to apoptosis upon treatment with DNA-
alkylating agents (46). And fourthly, Kriegl et al. (47) recently
demonstrated that TCF4 expression, based on immunohistochemical
analyses of primary CRCs, was a negative prognostic factor associ-
ated with shorter overall survival.
In summary, we provide the first evidence that the Wnt transcrip-
tion factor TCF4 is intricately involved in mediating resistance of
CRC cell lines and primary rectal cancers to radiation and
Fig. 5. Silencing of TCF4 results in a transcriptional deregulation of Wnt/TCF4 signaling in SW837. Silencing of TCF4 in SW837 (black) leads to
a transcriptional deregulation of the Wnt/TCF4 target genes MYC (downregulated, average fold-change of 2.7), Cyclin D1 (upregulated, average fold-change of
2.4) and DKK1 (downregulated, average fold-change of 18.4), whereas neither a prominent or consistent deregulation was observed in HT-29 (white). Plotted are
the normalized expression levels of TCF4 in four SSCs relative to the negative control shNeg (#DDCt). Data are presented as mean ± standard error of the mean.
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chemoradiotherapy. TCF4 therefore represents a promising molecular
target to sensitize a priori-resistant rectal cancers to irradiation. Al-
though we began to decipher the underlying cellular mechanisms
(Figure 6), future studies will ultimately elucidate the downstream
effects and regulation of TCF4 that mediate this important phenom-
enon, and they will further characterize the putative b-catenin inde-
pendency of this novel role of TCF4. If further validated, Wnt/TCF4
signaling inhibition may represent an effective strategy to increase the
fraction of patients that respond to multimodal treatment and improve
overall survival.
Supplementary material
Supplementary Tables S1–S4 and Figures S1–S4 can be found at
http://carcin.oxfordjournals.org/
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Figure S1. TCF4 Protein Expression Correlates Positively with Resistance of CRC cell lines to 
Chemoradiotherapy. 
(A) Representative Western blot analysis of eight colorectal cancer cell lines. (B) TCF4 protein expression was 
compared to their respective in vitro sensitivities to 5-FU-based chemoradiotherapy. With the exception of Caco-
2 and SW1116, TCF4 expression was positively correlated with treatment resistance. Results are shown for one 
representative experiment. 
 
Figure S2. Silencing of TCF4 Sensitizes SW837 and SW480 Cells to Irradiation 
Selected SCCs from SW837, SW480 and HT-29 were irradiated at clinically relevant doses of X-rays. A 
standard colony-forming assay demonstrated that silencing of TCF4 considerably increased the radiosensitivity 
of SW837 (P < 10-16, multiple linear regression model) and SW480 (P < 10-16), but not of HT-29 (P = 0.7). Data 
are presented as mean of three independent experiments ± SEM. 
 
Figure S3: TCF4 expression increases in SW480 and SW837 in response to irradiation. 
Representative Western blot analysis of CRC cell lines treated with 6 Gy of X-rays.  Notably, in SW837 and 
SW480, TCF4 protein expression levels increased in response to radiation, whereas the expression of TCF4 was 
unchanged in HT-29. 
 
Figure S4. Silencing of TCF4 Sensitizes SW837 Cells to Chemoradiotherapy 
Selected SCCs from SW837 and HT-29 were treated with 3 µM of 5-FU and irradiated at clinically relevant 
doses of X-rays). A standard colony-forming assay demonstrated that silencing of TCF4 considerably increased 
the chemoradiosensitivity of SW837 (P < 10-11, multiple linear regression model), but not of HT-29 (P = 0.7). 














SW837 2   TGCTGTTGACAGTGAGCGACGAACCTATCTCCAGATGAAATAGTGAAGCCACAGATGTATTTCATCTGGAGATAGGTTCGGTGCCTACTGCCTCGGA  
HT-29 1 TGCTGTTGACAGTGAGCGAGCACACATTGTCTCTAACAAATAGTGAAGCCACAGATGTATTTGTTAGAGACAATGTGTGCCTGCCTACTGCCTCGGA  
HT-29 2 TGCTGTTGACAGTGAGCGCCGTCACCAAGTCTTTAGAATATAGTGAAGCCACAGATGTATATTCTAAAGACTTGGTGACGATGCCTACTGCCTCGGA  
SW480 1 TGCTGTTGACAGTGAGCGAGCACACATTGTCTCTAACAAATAGTGAAGCCACAGATGTATTTGTTAGAGACAATGTGTGCCTGCCTACTGCCTCGGA  
SW480 2 TGCTGTTGACAGTGAGCGCCGTCACCAAGTCTTTAGAATATAGTGAAGCCACAGATGTATATTCTAAAGACTTGGTGACGATGCCTACTGCCTCGGA  
 
 
Table S1. Target sequences of Expression Arrest™ lentiviral short-hairpin RNA constructs targeting TCF4. 













Doubling Time (hr) 
 













SW837 + L-15 10 64 21 
SW480 + L-15 10 32 10 
 
* Rodrigues et al. ProcNatlAcadSci USA 1990; Liu and Bodmer ProcNatlAcadSci U S A 2006 





Table S3. 6XUYLYDOYDULDEOHVĮ DQGȕDQG'0)V 
Radiation Therapy 
         
         
SW480 Negative Control shRNA_1 SCC 1 Negative Control shRNA_1 SCC 2 Negative Control shRNA_2 SCC 1 Negative Control shRNA_2 SCC 2 
Į 0.051 0.311 0.143 0.145 0.148 0.374 0.110 0.250 
ȕ 0.033 0.004 0.017 0.036 0.014 0.001 0.024 0.039 
DMF 37% survival 1.58 1.28 1.78 1.62 
         
SW837 Negative Control shRNA_1 SCC 1 Negative Control shRNA_1 SCC 2 Negative Control shRNA_2 SCC 1 Negative Control shRNA_2 SCC 2 
Į 0.114 0.051 0.051 0.208 0.043 0.075 0.033 0.072 
ȕ 0.011 0.016 0.014 0.016 0.019 0.034 0.021 0.051 
DMF 37% survival 1.60 1.90 1.43 1.70 
         
         
HT29 Negative Control shRNA_1 SCC 1 Negative Control shRNA_1 SCC 2 Negative Control shRNA_2 SCC 1 Negative Control shRNA_2 SCC 2 
Į -0.008 0.112 0.019 -0.018 -0.001 -0.078 0.033 0.197 
ȕ 0.034 0.021 0.037 0.040 0.032 0.065 0.031 0.015 
DMF 37% survival 1.20 1.08 1.18 1.33 
         
5-FU based Chemoradiotherapy 
         
         
SW837 Negative Control shRNA_1 SCC 1 Negative Control shRNA_1 SCC 2 Negative Control shRNA_2 SCC 1 Negative Control shRNA_2 SCC 2 
Į 0.181 0.238 0.216 0.329 0.125 0.156 0.239 0.351 
ȕ 0.008 0.015 0.004 0.012 0.013 0.023 0.002 0.046 
DMF 37% survival 1.32 1.59 1.35 1.54 
         
HT29 Negative Control shRNA_1 SCC 1 Negative Control shRNA_1 SCC 2 Negative Control shRNA_2 SCC 1 Negative Control shRNA_2 SCC 2 
Į 0.081 0.101 0.081 0.056 0.081 0.100 0.081 0.157 
ȕ 0.015 0.013 0.015 0.018 0.015 0.009 0.015 0.000 
DMF 37% survival 1.05 1.02 1.07 1.08 
Table S4 
 
Symbol Accession Number Forward Primer Sequence Reverse Primer Sequence 
DKK1 NM_012242 CATCAGACTGTGCCTCAGGA   CCACAGTAACAACGCTGGAA   
CCND1 
NM_053056 CTGAGGAGCCCCAACAACT TGGGGTCCATGTTCTGCT   
MYC NM_002467 CAAGCAGAGGAGCAAAAG CGCACAAGAGTTCCGTAG 
HPRT1 NM_000194 TGACACTGGCAAAACAATGCA GGTCCTTTTCACCAGCAAGCT 
YWHAZ NM_145690, NM_003406, 
NM_001135702, NM_001135701, 
NM_001135700, NM_001135699  
ACTTTTGGTACATTGTGGCTTCAA CCGCCAGGACAAACCAGTAT 
GAPDH NM_002046 CCACATCGCTCAGACACCAT CCAGGCGCCCAATACG 
 
Table S4. Primer sequences for real-time PCR analysis. 
 
 
